Claims for Patent: 4,879,308

Summary for Patent: 4,879,308

Title:	Aqueous nitroglycerin injection and manufacturing process
Abstract:	Nitroglycerin injection that is free of the customary organic solvents and has an extended shelf life of at least 1 year, consisting essentially of water, lactose, and nitroglycerin. Sodium chloride or dextrose may be added during manufacture or upon diluting with an infusion. Commerically safe manufacture and stable dispersion are assured by mixing lactose adsorbate, containing nitroglycerin, with water at high shear so that no nitroglycerin droplets coalesce. Stability is maintained by filtering and filling operations using nonreactive, nonleaching, nonadsorptive materials.
Inventor(s):	Alam; Abu S. (Libertyville, IL), Joshi; Utpal G. (Hanover Park, IL), Mehta; Jairaj U. (Forest Park, IL), Sayeed; Fakrul A. A. (Mundelein, IL), Kapoor; John N. (Lake Forest, IL)
Assignee:	LyphoMed, Inc. (N/A)
Application Number:	07/084,631
Patent Claims:	1. An aqueous solution of nitroglycerin that is sterile, nonpyrogenic, adjustable for tonicity, and suitable for intravenous injection in mammals requiring treatment with nitroglycerin consisting essentially of sterile water for injection, lactose, and nitroglycerin, said nitroglycerin being present at a concentration of at least about 0.5 mg/ml; the solution containing no organic solvents and being stable for at least 1 year. 2. The aqueous solution of nitroglycerin as claimed in claim 1 wherein the nitroglycerin is present in the solution in an amount of from about 0.5 to about 1.0 milligrams of nitroglycerin per milliliter of solution. 3. An aqueous solution of nitroglycerin that is sterile, nonpyrogenic, adjusted for tonicity, and suitable for intravenous injection in mammals requiring treatment with nitroglycerin consisting essentially of sterile water for injection, lactose, sodium chloride, and nitroglycerin, said nitroglycerin being present at a concentration of at least 0.5 mg/ml; the solution containing no organic solvents and being stable for at least 1 year. 4. The aqueous solution of nitroglycerin as claimed in claim 3 wherein the nitroglycerin is present in the solution in an amount of from about 0.5 to about 1.0 milligrams of nitroglycerin per milliliter of solution. 5. An aqueous solution of nitroglycerin that is sterile, nonpyrogenic, adjusted for tonicity, and suitable for intravenous injection in mammals requiring treatment with nitroglycerin consisting essentially of sterile water for injection, lactose, dextrose, and nitroglycerin, said nitroglycerin being present at a concentration of at least about 0.5 mg/ml; the solution containing no organic solvents and being stable for at least 1 year. 6. The aqueous solution of nitroglycerin as claimed in claim 5 wherein the nitroglycerin is present in the solution in an amount of from about 0.5 to about 1.0 milligrams of nitroglycerin per milliliter of solution. 7. An aqueous solution of nitroglycerin that is sterile, nonpyrogenic, and suitable for use in intravenous injection in mammals requiring treatment with nitroglycerin, consisting essentially of (1) a solvent selected from the group comprising sterile water for injection, saline solution and dextrose solution, (2) lactose, and (3) nitroglycerin, said nitroglycerin being present at a concentration of at least about 0.5 mg/ml; the solution containing no organic solvents other than lactose and being stable for at least 1 year. 8. The aqueous solution of nitroglycerin as claimed in claim 7 wherein the nitroglycerin is present in the solution in an amount of from about 0.5 to about 1.0 milligrams of nitroglycerin per milliliter of solution. 9. A sterile and nonpyrogenic aqueous solution of nitroglycerin that is stable for at least 1 year and consists essentially of nitroglycerin, said nitroglycerin being present at a concentration of at least about 0.5 mg/ml, water, and a component selected from the group consisting of lactose, lactose and sodium chloride, and lactose and dextrose. 10. The aqueous solution of nitroglycerin as claimed in claim 9 wherein the nitroglycerin is present in the solution in an amount of from about 0.5 to about 1.0 milligrams of nitroglycerin per milliliter of solution. 11. A process for making an aqueous solution of nitroglycerin that is sterile, nonpyrogenic, and therefore suitable for intravenous injection in mammals requiring treatment with nitroglycerin, comprising: a. dissolving a mixture of nitroglycerin and lactose in sterile water for injection using high shear agitation sufficient to completely dissolve the nitroglycerin without allowing nitroglycerin droplets to coalesce or to reach local concentrations above saturation, b. adding sterile water for injection as necessary to adjust the nitroglycerin concentration using continuous agitation, c. filtering the solution to sterilize it through a filter using nonadsorptive tubing, d. aseptically filling sterile, depyrogenated, glass ampules or glass vials, and e. stoppering the glass vials or ampules with nonreactive, nonleaching elastomeric closures. 12. The process of claim 11 wherein a nitrogen blanket over the mixture is maintained throughout the process. 13. The process of claim 11 wherein the mixture of nitroglycerin and lactose comprises 1 part nitroglycerin and 9 parts lactose. 14. The process of claim 11 wherein the mixture of nitroglycerin and lactose is a powder that comprises less than 1 part nitroglycerin in 9 parts lactose. 15. The process of claim 14 wherein a quantity of the nitroglycerin and lactose mixture is dissolved in water sufficient to form a solution having a concentration of nitroglycerin of from about 0.5 to about 1.0 milligram of nitroglycerin per milliliter of water. 16. The process of claim 11 wherein a component selected from the group consisting of sodium chloride and dextrose is added to the solution after step (a) and before step (b), using continuous agitation. 17. The process of claim 11 wherein the sterile water for injection of step 1 further comprises sodium chloride. 18. The process of claim 11 wherein the sterile water for injection of step 1 further comprises dextrose. 19. The process of claim 11 wherein the solution is filtered through a 0.2 micron filter. 20. The process of claim 19 wherein the solution is filtered through a 0.45 micron prefilter before being filtered through a 0.2 micron filter.

Details for Patent 4,879,308

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23